We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In patients with type 2 diabetes and an ICD or CRT-D, ...

Higher baseline serum magnesium levels are linked to a higher risk for cardiac events in HFmrEF/HFpEF, while empagliflozin treatment shows a lower risk for these events in those with higher magnesium.

Data from real-world practice and a meta-analysis of randomized controlled trials concur. Empagliflozin may reduce the risk of nephrolithiasis in patients with type 2 diabetes, according to new ...

Empagliflozin offers cardiorenal benefits for up to 12 months after discontinuation among chronic kidney disease patients at risk for progression. HealthDay News — Empagliflozin continues to offer ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment with ...

For decades, investigators have searched for a new therapeutic agent against diabetic kidney disease. While angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have ...

The advantage of empagliflozin, and the sodium glucose cotransporter 2 class generally, is that its unique mechanism expels excess glucose through the urine, thus offering the possibility of reducing ...

Lungs Heart The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes. Full results from the phase 3 ...

Please provide your email address to receive an email when new articles are posted on . The benefits of empagliflozin compared with placebo for HF with reduced ejection fraction occurred regardless of ...

The EMPEROR-Preserved trial of empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) met its primary endpoint, according to top-line results released today, meaning a therapy with specific ...

Among 34,239 matched pairs, the risk of incident nonproliferative diabetic retinopathy was not different between patients taking empagliflozin or DPP-4 inhibitors (HR 1.04, 95% CI 0.94-1.15) over a ...